Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LN-145 in Advanced Cervical Carcinoma
NCT03108495Phase 2Terminated
- Sponsor
- Iovance Biotherapeutics
- Start
- Jun 2017
- Primary completion
- Aug 2025
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 8
01
Overview
A Phase 2 trial of LN-145 in cervical carcinoma, sponsored by Iovance Biotherapeutics. Started Jun 2017; status: terminated.
02
Drugs
LN-145
03
Conditions
cervical carcinoma
Beyond the preview
Go deeper on NCT03108495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108495.